Associations - Bavencio (avelumab)

No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	avelumab Sensitive: A2 - Guideline avelumab Sensitive : A2	avelumab Sensitive: A2 - Guideline avelumab Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: B - Late Trials avelumab + axitinib Sensitive : B	avelumab + axitinib Sensitive: B - Late Trials avelumab + axitinib Sensitive : B
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	avelumab Resistant: B - Late Trials avelumab Resistant : B	avelumab Resistant: B - Late Trials avelumab Resistant : B
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	avelumab Sensitive: B - Late Trials avelumab Sensitive : B	avelumab Sensitive: B - Late Trials avelumab Sensitive : B
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	avelumab Sensitive: B - Late Trials avelumab Sensitive : B	avelumab Sensitive: B - Late Trials avelumab Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	avelumab Sensitive: B - Late Trials avelumab Sensitive : B	avelumab Sensitive: B - Late Trials avelumab Sensitive : B
HLA-A*03	Renal Cell Carcinoma	HLA-A*03	Renal Cell Carcinoma	avelumab + axitinib Resistant: B - Late Trials avelumab + axitinib Resistant : B	avelumab + axitinib Resistant: B - Late Trials avelumab + axitinib Resistant : B
HLA-A*03	Renal Cell Carcinoma	HLA-A*03	Renal Cell Carcinoma	avelumab Resistant: B - Late Trials avelumab Resistant : B	avelumab Resistant: B - Late Trials avelumab Resistant : B
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
PD-L1 expression	Merkel Cell Carcinoma	PD-L1 expression	Merkel Cell Carcinoma	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLD1 mutation	Solid Tumor	POLD1 mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
POLE mutation	Endometrial Cancer	POLE mutation	Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
HER-2 amplification	Esophageal Cancer	HER-2 amplification	Esophageal Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
NRAS mutation	Pancreatic Cancer	NRAS mutation	Pancreatic Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
BRCA1 mutation	Solid Tumor	BRCA1 mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
BRCA2 mutation	Solid Tumor	BRCA2 mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2

Bavencio (avelumab)

Associations
(89)

Associations
(89)

Bavencio (avelumab)

Associations(89)

Associations(89)

Associations
(89)

Associations
(89)